By Karen Roman
March Biosciences said it elected Peter Olagunju as chair of its Board of Directors, following a $28.4 million Series A financing the company secured for its lead cancer therapy.
Mr. Olagunju has over 20 years of experience in cell and gene therapy and is currently the CEO of Stealth Mode Biotech in Boston, the company stated.
“He becomes Board Chair at a pivotal time as we leverage our recent Series A funding to initiate a Phase 2 clinical trial for MB-105, expand our pipeline and strengthen our manufacturing capabilities,” said Sarah Hein, March Bio’s co-founder and Chief Executive Officer.
Contact:
